

Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors

THESIS

Submitted for fulfillment of Master Degree of

Pediatric Hematology & Oncology

By :**AHMED HUSSEIN AL GAMMAL**

(M.B., B.Ch)

National Cancer Institute

Cairo University

Supervised By

Prof .DR .EMAD NABIL EBEID

Professor of Pediatric Oncology

National Cancer Institute

Cairo University

DR .HANY ABD AL RAHMAN

Lecturer of Pediatric Oncology

National Cancer Institute

Cairo University

DR .Nahla El Sharqawy

Consultant of clinical pathology

National cancer institute

Cairo University

Cairo

(2010)

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

وَفَوْقَ كُلِّ ذِي عِلْمٍ عَلِيمٌ

صَدَقَ اللَّهُ الْعَظِيمُ

سورة يوسف الآية رقم: (٧٦)

To my mother and father

ACKNOWLEDGEMENT

First and foremost thanks are to GOD the most beneficent kind and merciful.

Word are never be able to express my deepest gratitude to all those who helped me during preparation of this study.

I am most grateful to Prof.Dr .Emad Nabil Ebeid, professor of pediatric oncology, National Cancer Institute, Cairo University, who kindly supervised and motivated the performance of the work with keen interest and indispensable advice.

I am gratefully honored to express my sincere appreciation to Dr .Hany Abd Alrahman, lecturer of pediatric oncology, National Cancer Institute, Cairo University, for his supervision and guidance.

I would like to express my thanks to Dr .Nahla EL Sharkawy, consultant of clinical pathology, National Cancer Institute, Cairo University, for her valuable scientific supervision and guidance.

Finally, I have to extend by greatfuness and deep thanks to all my professors in pediatric oncology department for their continuous help, encourage and education.

List of contents

Subject	Page
Abstract.....	1
Introduction.....	3
Aim of work.....	5
Review of literature.....	6
• Epidemiology.....	6
• Pathobiology.....	11
• Clinical manifestation.....	26
• Diagnosis.....	32
• Prognostic factors.....	35
• Treatment.....	42
• Minimal residual disease.....	59
Patients and methods.....	80
Results.....	105
Discussion.....	134
Summary and conclusion.....	148
References.....	151
Arabic summary.....	176

List of tables

Table		Page
Table :1	French-American-British classification of lymphoblastic leukemia	12
Table :2	Clinical and laboratory features at diagnosis in children with ALL	31
Table :3	Most Commonly Used Breakpoint Fusion Genes for Reverse Transcription–Polymerase Chain Reaction Analysis of Minimal Residual Disease	61
Table :4	Immunophenotypic Markers Currently Used to Study MRD in Children with ALL	72
Table :5	Immunophenotypic Combinations Used to Study MRD in T -ALL	74
Table :6	data collected serially from patients during study	82
Table :7	Dosages, schedules and routes of medication at induction	87
Table :8	Dosages, schedules and routes :Weeks 1 to 6 and 10 to 16	94
Table :9	Dosages, schedules and routes :Weeks 7 to 9	95
Table :10	Dosages, schedules and routes :Weeks 17 to 19	95
Table :11	Dosages, schedules and routes :weeks 7 to 9 and Weeks 17 to 19	98
Table :12	Treatment)weeks 21 to end of therapy(101
Table :13	Dosages, schedules and routes of maintenance	101
Table :14	the range, mean, median, and age groups of cases	105
Table :15	sex distribution of cases	106
Table :16	clinical presentations of cases	107

Table	Page
Table :17 frequency, percentage, range, mean, and median of initial total leucocytic count	108
Table :18 frequency and percentage of morphology of BMA at presentation	109
Table :19 frequency and percentage of cellularity of BMA at presentation	109
Table :20 frequency and percentage of various IPT classifications	110
Table :21 frequency and percentage of all B ALL versus all T ALL cases	110
Table :22 markers coexpressed on blast cells at presentation	111
Table :23 CD34, MHC2 frequency and percentage	111
Table :24 CSF status at presentation)frequency and percentage(112
Table :25 various groups of DNA index at presentation	112
Table :26 frequency and percentage of cytogenetic	113
Table :27 frequency and percentage of bone marrow cellularity day 15	114
Table :28 frequency and percentage of bone marrow blasts at day15	114
Table :29 frequency and percentage of bone marrow cellularity day 42	114
Table :30 frequency and percentage of bone marrow blasts at day 42	115
Table :31 minimal residual disease at bone marrow day 15	115
Table :32 quantitation of minimal residual disease at day 15	115
Table:33 classification of MRD +ve at day 15	116
Table:34 minimal residual disease at bone marrow day 42	116

Table		Page
Table :35	minimal residual disease at day 15 and its relation to other prognostic criteria	118
Table :36	relapse free survivals in relation to MRD day 15	119
Table :37	over all survival in relation to MRD day 15	119
Table :38	minimal residual disease at day 42 and its relation to other prognostic criteria	127
Table :39	Relapse free survivals in relation to MRD day 42	128
Table :40	overall survival in relation to MRD day 42	128

List of figures

Figure		Page
Figure :1	Normal immunophenotypic patterns in hematogones	68
Figure :2	Bone marrow samples from 4 patients were obtained on day 19	69
Figure :3	Differences in antigen expression between normal and leukemic cells	70
Figure :4	phenotypic derangements of malignant B-cells exploitable for MRD assessment	71
Figure :5	Four-color FCM MRD-analysis in T-ALL	74
Figure :6	Road map of induction chemotherapy	88
Figure :7	Road map of consolidation chemotherapy	93
Figure :8	Road map of continuation chemotherapy for standard and high risk) W 1 to W 65(96
Figure :9	Road map of continuation chemotherapy for standard and high risk) W 66 till end(98
Figure :10	Road map of continuation chemotherapy for low risk)W1 to W 65(99
Figure :11	Road map of continuation chemotherapy for low risk)W 66 till end(100
Figure :12	cellularity of bone marrow at presentation	109
Figure :13	MRD classification at day 15	116
Figure :14	Eighteen months, relapse free survival according to MRD at day 15	124
Figure :15	Eighteen months, overall survival according to MRD at day 15	126
Figure :16	Eighteen months, relapse free survival according to MRD at day 42	132
Figure :17	Eighteen months, overall survival according to MRD at day 42	133

List of abbreviations

AIDS:	Acquired immunodeficiency syndrome
ALL:	Acute lymphoblastic leukemia
AML:	Acute myeloid leukemia
ANC:	Absolute Neutrophilic Count
B-ALL:	B cell Acute Lymphoblastic Leukemia
BCR:	Breakpoint Cluster Region
BFM:	Berlin-Frankfurt-Muenster
BM:	Bone Marrow
BMT:	Bone Marrow Transplantation
CD:	Cluster of Differentiation
CIBMTR	Center for International Blood and Marrow Transplant Research
CML:	Chronic Myeloid Leukemia
CNS:	Central Nervous System
COG:	Children oncology group
CR:	Complete Remission
CSF:	Cerebrospinal Fluid
CT:	Computed Tomography
DFCI:	Dana-Farber Cancer Institute
DFS:	Disease Free Survival
DNA:	Deoxyribonucleic Acid
EBV:	Epstein-Barr virus
EFS:	Event Free Survival
FAB:	French, American, British classification
FCM:	Flow cytometry
FISH:	fluorescence in situ hybridization
FSC:	Forward scatter
GST:	glutathione S-transferase

GVHD:	Graft Versus Host Disease
GVL:	Graft Versus Leukemia
HDAC:	High Dose Ara-C
HDMTX:	High Dose Methotrexate
HIV:	human immunodeficiency virus
HR:	High Risk
HLA:	human lymphocyte antigen
HSCT:	Hematopoietic Stem Cell Transplantation
HTLV:	Human lymphotropic viruses
Ig:	Immunoglobulin
IM:	Intramuscular
IT:	Intrathecal
I.V:	Intravenous
LCR:	Ligase Chain Reaction
MLL:	Mixed lineage leukemia
MALT:	mucosa-associated lymphoid tumors
MP:	mercaptopurine
MRC:	Medical Research Council
LDH:	Lactate Dehydrogenase
MoAB:	Monoclonal Antibodies
MRD:	Minimal Residual Disease
MRI:	Magnetic Resonance Imaging
MTX:	Methotrexate
NK:	natural killer
OS:	Overall survival
PAS:	Periodic Acid Schiff
PB:	Peripheral Blood
PCR:	Polymerase Chain Reaction
Ph:	Philadelphia Chromosome

POG:	Pediatric oncology group
PR:	Partial Remission
RNA:	Ribonucleic acid
RQ-PCR:	Real time Quantitative polymerase Chain Reaction
SCT:	Stem Cell Transplantation
SKY:	spectral karyotyping
SR:	Standard Risk
SSC:	Sideward scatter
SJCRH	St Jude Children Research hospital
T-ALL:	T cell Acute Lymphoblastic Leukemia
TBI:	Total Body Irradiation
TCR:	T – Cell Receptors
TdT:	Terminal Deoxynucleotidyl Transferase
TG:	thioguanine
TLC:	Total Leucocytic Count
TPMT:	Thiopurine methyl transferase
WBC:	White Blood Cells
WHO:	World Health Organization
WT1:	Wilms tumor 1

ABSTRACT

BACKGROUND :ALL is the most common cancer diagnosed in children and represents 23 %of cancer diagnoses among children younger than 15 years . Better understanding of the characteristics of leukemic cells have led to novel ways of detecting morphologically occult leukemic cells)i.e., minimal residual disease, MRD (by detecting abnormalities in protein expression detectable by flow cytometry .MRD is the presence of cells following chemotherapy below the level of morphologic detection .Flow cytometric techniques which assess MRD should achieve a sensitivity of at least 1/10000 leukemic cells in bone marrow) 0.01 .(% MRD has emerged as the most powerful tool for assessing response to chemotherapy, and MRD positivity has been demonstrated to be the strongest independent risk factor for relapse among other clinical and biological risk factors . Detection of leukemia associated phenotypes via flow cytometry is applicable in almost all cases, fast, and relatively inexpensive.

PURPOSE :The aim of this study was to determine if the presence of minimal residual disease by flow cytometry at bone marrow of cases with acute lymphoblastic leukemia in children during treatment had any correlation with various clinical and biological risk factors such as :age, gender, initial TLC, initial CSF, IPT, DNA index, cytogenetics and the effect of minimal residual disease on outcome of ALL patients regarding relapse free survival and overall survival.

PATIENTS AND METHODS :Between the periods from January 2009 to February 2010, seventy five children who presented to the pediatric oncology outpatient clinic, National Cancer Institute, Cairo University, were enrolled in the study .Patients were 46 males)61.3 (%and 29 females)38.7 (%with a male :female ratio 1.58:1 .Their ages ranged from 4 months to 18 years with mean age of 8.5

years .All patients received therapy according to the St .Jude Total XV protocol modified .They were evaluated for response to treatment by minimal residual disease at bone marrow at day 15 and at end of induction on day 42 .

RESULTS :Twenty four patients were MRD positive at bone marrow at day 15 and 51 patients were MRD negative .It was significant correlation that the 18 months relapse free survivals for these patients were 67.4 %for positive patients and 86.7 %for negative patients)P value =0.034.(quantification of the level of MRD positivity was also of significant value as patients whose level was between 10^{-4} to 10^{-3} had RFS of 73.2 %while patients whose level was above 10^{-3} had RFS of 53.6) %P value =0.043 .(

At day 42 MRD, 18 cases were positive and 57 cases were negative and it was highly significant correlation that the 18 months RFS of these two groups were 57.8 %and 88 %respectively)P value =0.002 .(MRD was studied in relation to the common clinical and biological risk factors of ALL and it was found that MRD post induction was frequently present with unfavorable risk criteria but all of these were of low significant value except for initial TLC, DNA index)P value =0.032, 0.006 respectively .(Post induction MRD was an independent prognostic factor for ALL patients regarding RFS and OS.

CONCLUSIONS :The presence of minimal residual disease at day 15 and post induction at day 42 can affect the outcome of patients with ALL regarding RFS and OS and its presence is frequently found in patients with adverse clinical and biological factors but it was revealed that MRD post induction was an independent prognostic factors among these factors to detect the outcome of patients.

Key words :ALL -minimal residual disease -flow cytometry

Introduction